Table 3 Intra- and postoperative outcomes according to treatment group.
Before propensity score matching | After propensity score matching | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Lap (n = 51) | Hybrid (n = 154) | Open (n = 442) | p value | Lap (n = 42) | Hybrid (n = 81) | p value | Lap (n = 48) | Open (n = 136) | p value | |
Operating time (min), median (range) | 300 (162–670) | 363 (90–924) | 316 (60–725) | 0.001 | 315 (162–670) | 330 (90–679) | 0.707 | 308 (162–670) | 279 (82–725) | 0.070 |
EBL (mL), median (range) | 300 (20–1500) | 400 (50–1500) | 400 (10–14,500) | < 0.001 | 325 (20–1500) | 300 (50–1400) | 0.516 | 300 (20–1500) | 350 (30–14,500) | 0.063 |
Transfusion, n (%) | 5 (9.8) | 12 (7.8) | 63 (14.3) | 0.094 | 4 (9.5) | 5 (6.2) | 0.489 | 5 (10.4) | 19 (14.0) | 0.530 |
Colorectal tumor | ||||||||||
p/ypT stage, n (%) | < 0.001 | 0.508 | 0.158 | |||||||
T1–2 | 8 (15.7) | 8 (5.2) | 14 (3.2) | 5 (11.9) | 6 (7.4) | 5 (10.4) | 6 (4.4) | |||
T3–4 | 43 (84.3) | 146 (94.8) | 428 (96.8) | 37 (88.1) | 75 (92.6) | 43 (89.6) | 130 (95.6) | |||
p/ypN stage, n (%) | 0.299 | 0.937 | 0.626 | |||||||
N0 | 8 (15.7) | 18 (11.7) | 75 (17.0) | 6 (14.3) | 12 (14.8) | 7 (14.6) | 24 (17.6) | |||
N1–2 | 43 (84.3) | 136 (88.3) | 367 (83.0) | 36 (85.7) | 69 (85.2) | 41 (85.4) | 112 (82.4) | |||
Differentiation, n (%) | 0.271 | 0.307 | 0.224 | |||||||
WD/MD | 45 (88.2) | 146 (94.8) | 412 (93.2) | 37 (88.1) | 76 (93.8) | 42 (87.5) | 127 (93.4) | |||
PD/Mucinous/SRC | 6 (11.8) | 8 (5.2) | 30 (6.8) | 5 (11.9) | 5 (6.2) | 6 (12.5) | 9 (6.6) | |||
Liver metastases | ||||||||||
Maximal lesion size (cm), median (range) | 2.0 (0.5–7.0) | 2.0 (0.3–16.1) | 2.3 (0.1–15.4) | 0.011 | 2.0 (0.5–7.0) | 1.9 (0.3–16.1) | 0.669 | 2.0 (0.5–7.0) | 2.0 (0.4–12.0) | 0.937 |
Positive RM, n (%) | 5 (9.8) | 27 (17.5) | 63 (14.3) | 0.280 | 5 (11.9) | 12 (14.8) | 0.657 | 5 (10.4) | 11 (8.1) | 0.567 |
Length of RM (cm), median (range) | 0.40 (0–3.5) | 0.50 (0–8.5) | 0.40 (0–11.0) | 0.194 | 0.4 (0–3.5) | 0.6 (0–8.0) | 0.252 | 0.4 (0–3.5) | 0.5 (0–9.1) | 0.442 |
Postop hospital stay (days), median (range) | 8 (6–21) | 11 (5–51) | 12 (5–79) | < 0.001 | 8 (6–21) | 11 (7–40) | < 0.001 | 8 (6–21) | 11 (5–79) | < 0.001 |
Morbidity*, n (%) | 12 (23.5) | 48 (31.2) | 170 (38.5) | 0.046 | 12 (28.6) | 21 (25.9) | 0.754 | 12 (25.0) | 46 (33.8) | 0.258 |
Colorectal morbidity | 2 (3.9) | 4 (2.6) | 10 (2.3) | 0.765 | 2 (4.8) | 1 (1.2) | 0.268 | 2 (4.2) | 1 (0.7) | 0.167 |
Anastomotic leakage | 2 (3.9) | 4 (2.6) | 5 (1.1) | 0.212 | 2 (4.8) | 1 (1.2) | 0.268 | 2 (4.2) | 1 (0.7) | 0.167 |
Intestinal ischemia | 0 (0) | 0 (0) | 2 (0.5) | 0.628 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
Intestinal stricture | 0 (0) | 0 (0) | 2 (0.5) | 0.628 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
Anastomotic bleeding | 0 (0) | 0 (0) | 1 (0.2) | 0.793 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
Liver morbidity | 3 (5.9) | 3 (1.9) | 17 (3.8) | 0.354 | 3 (7.1) | 1 (1.2) | 0.115 | 3 (6.3) | 3 (2.2) | 0.184 |
Biliary collection | 3 (5.9) | 1 (0.6) | 13 (2.9) | 0.098 | 3 (7.1) | 0 (0) | 0.038 | 3 (6.3) | 3 (2.2) | 0.184 |
Biliary obstruction | 0 (0) | 0 (0) | 1 (0.2) | 0.793 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
Hepatic bleeding | 0 (0) | 2 (1.3) | 0 (0) | 0.040 | 0 (0) | 1 (1.2) | > 0.999 | 0 (0) | 0 (0) | N.A |
Hepatic failure | 0 (0) | 0 (0) | 3 (0.7) | 0.497 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
Portal vein thrombosis | 0 (0) | 0 (0) | 2 (0.5) | 0.628 | 0 (0) | 0 (0) | N.A | 0 (0) | 0 (0) | N.A |
General morbidity | 7 (13.7) | 44 (28.6) | 144 (32.6) | 0.019 | 7 (16.7) | 19 (23.5) | 0.382 | 7 (14.6) | 43 (31.6) | 0.023 |
Wound Cx | 1 (2.0) | 14 (9.1) | 70 (15.8) | 0.005 | 1 (2.4) | 8 (9.9) | 0.164 | 1 (2.1) | 18 (13.2) | 0.028 |
Prolonged ileus | 1 (2.0) | 13 (8.4) | 32 (7.2) | 0.291 | 1 (2.4) | 5 (6.2) | 0.663 | 1 (2.1) | 10 (7.4) | 0.293 |
Urinary retention | 3 (5.9) | 16 (10.4) | 20 (4.5) | 0.031 | 3 (7.1) | 6 (7.4) | > 0.999 | 3 (6.3) | 7 (5.1) | 0.722 |
Cardiovascular Cx | 0 (0) | 0 (0) | 3 (0.7) | 0.497 | 0 (0) | 0 (0) | N.A | 0 (0) | 2 (1.5) | > 0.999 |
Pulmonary Cx | 2 (3.9) | 2 (1.3) | 19 (4.3) | 0.221 | 2 (4.8) | 0 (0) | 0.115 | 2 (4.2) | 6 (4.4) | > 0.999 |
Neuropsychiatric Cx | 0 (0) | 0 (0) | 3 (0.7) | 0.497 | 0 (0) | 0 (0) | N.A | 0 (0) | 1 (0.7) | > 0.999 |
Clavien-Dindo classification, n (%) | 0.045 | 0.703 | 0.508 | |||||||
Grade < 3 | 7 (13.7) | 38 (24.7) | 108 (24.4) | 7 (16.7) | 15 (18.5) | 7 (14.6) | 29 (21.3) | |||
Grade ≥ 3 | 5 (9.8) | 10 (6.5) | 61 (13.8) | 5 (11.9) | 6 (7.4) | 5 (10.4) | 17 (12.5) | |||
Mortality†, n (%) | 0 (0) | 0 (0) | 6 (1.4) | 0.246 | 0 (0) | 0 (0) | N.A | 0 (0) | 1 (0.7) | > 0.999 |